NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
3-[(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidin-1-ium bromide
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
Asecryl
|
Gastrodyn
|
Nodapton
|
Robanul
|
Robinal
|
Robinul
|
Tarodyl
|
Tarodyn
|
|
|
Synonyms
|
3-[(2-Cyclopentyl-2-hydroxy-2-phenylacetyl)oxy]-1,1-dimethylpyrrolidinium Bromide
|
Asecryl
|
NVA 237
|
Nodapton
|
Robanul
|
Robinul
|
Tarodyl
|
Tarodyn
|
Glycopyrrolate Bromide
|
Glycopyrronium bromide
|
glycopyrrolate
|
Glycopyrrolate
|
α-cyclopentylmandelic acid ester with 3-hydroxy-1,1-dimethylpyrrolidinium bromide
|
1-methyl-3-pyrrolidyl α-cyclopentylmandelate methobromide
|
1-methyl-3-pyrrolidyl α-phenyl-α-cyclopentylglycolate methobromide
|
3-(2-phenyl-2-cyclopentylglycoloyloxy)-1,1-dimethylpyrrolidinium bromide
|
3-hydroxy-1,1-dimethylpyrrolidinium bromide α-cyclopentylmandelate
|
AHR-504
|
Copyrrolate
|
Gastrodyn
|
NSC 250836
|
NSC 251251
|
NSC 251252
|
NVA-237
|
Glycopyrrolate
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
11.533273
|
H Acceptors
|
2
|
H Donor
|
1
|
LogD (pH = 5.5)
|
-1.4080803
|
LogD (pH = 7.4)
|
-1.4074817
|
Log P
|
-1.408088
|
Molar Refractivity
|
101.0809 cm3
|
Polarizability
|
35.6508 Å3
|
Polar Surface Area
|
46.53 Å2
|
Rotatable Bonds
|
5
|
Lipinski's Rule of Five
|
true
|
Log P
|
-1.2
|
LOG S
|
-5.57
|
Solubility (Water)
|
9.44e-04 g/l
|
DETAILS
DETAILS
DrugBank
Sigma Aldrich
TRC
DrugBank -
DB00986
|
Item |
Information |
Drug Groups
|
approved; investigational |
Description
|
Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. A muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics. [PubChem] |
Indication |
For use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. |
Pharmacology |
Glycopyrrolate decreases acid secretion in the stomach. Hence it can be used for treating ulcers in the stomach and small intestine, in combination with other medications. In anesthesia, glycopyrrolate injection serves as a preoperative antimuscarinic operation that reduces salivary, tracheobronchial, and pharyngeal secretions, as well as decreases the acidity of gastric secretions blocks cardiac vagal inhibitory reflexes during intubation |
Toxicity |
Side effects include dry mouth, difficult urinating, heachaches, diarrhea and constipation. The medication also induces drowsiness or blurred vision. LD50=709 mg/kg (rat, oral). |
Affected Organisms |
• |
Humans and other mammals |
|
Absorption |
Rapidly absorbed (1-2 minutes) after intravenous injection |
Half Life |
0.6-1.2 hours |
References |
• |
Ali-Melkkila T, Kanto J, Iisalo E: Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993 Oct;37(7):633-42.
[Pubmed]
|
|
External Links |
|
|
Sigma Aldrich -
SML0029
|
Biochem/physiol Actions Glycopyrrolate is long-acting muscarinic antagonist (LAMA). It is kinetically selective muscarinic M3 receptor antagonist. |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Ali-Melkkila T, Kanto J, Iisalo E: Pharmacokinetics and related pharmacodynamics of anticholinergic drugs. Acta Anaesthesiol Scand. 1993 Oct;37(7):633-42. Pubmed
- • Kaltiala, E., et al.: J. Pharm. Pharmacol., 26, 352 (1974)
- • Kongsrud, F., et al.: Acta Anaesthesiol. Scand., 26, 620 (1974)
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent